Prognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients

Table 2

Cox proportional-danger model analysis for hepatocellular carcinoma.

	Univariable analysis				Multivariable analysis
	Hepatocellular carcinoma-overall survival		Hepatocellular carcinoma-specific survival		Hepatocellular carcinoma-overall survival		Hepatocellular carcinoma-specific survival
	HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)
Age (years)		<0.001		<0.001
00–50	Reference		Reference		Reference	<0.001	Reference
51–60	1.14 (1.05–1.25)	0.003	1.15 (1.04–1.27)	0.006	1.22 (1.12.1.33)	<0.001	1.12 (1.09–1.33)	<0.001
61–70	1.17 (1.07–1.27)	0.001	1.15 (1.04–1.27)	0.005	1.19 (1.09–1.30)	<0.001	1.15 (1.04–1.27)	0.005
70+	1.69 (1.54–1.84)	<0.001	1.75 (1.58–1.93)	<0.001	1.40 (1.28–1.53)	<0.001	1.36 (1.23–1.50)	<0.001
Gender		<0.001		<0.001
Female	Reference		Reference		Reference		Reference
Male	1.12 (1.07–1.18)	<0.001	1.14 (1.07–1.20)	<0.001	1.06 (1.01–1.12)	0.018	1.07 (1.01–1.14)	0.023
Race		<0.001		<0.001
White	Reference		Reference		Reference		Reference
Black	0.84 (0.80–0.87)	<0.001	0.84 (0.80–0.88)	<0.001	0.91 (0.87–0.95)	<0.001	0.92 (0.88–0.97)	0.001
Others	0.80 (0.76–0.84)	<0.001	0.78 (0.74–0.83)	<0.001	0.91 (0.86–0.95)	<0.001	0.90 (0.84–0.95)	<0.001
Marital status		<0.001		<0.001
Married	Reference		Reference		Reference		Reference
Single	1.29 (1.24–1.35)	<0.001	1.31 (1.25–1.37)	<0.001	1.11 (1.06–116)	<0.001	1.10 (1.05–1.16)	<0.001
Tumor size (cm)		<0.001		<0.001
0–2	Reference		Reference		Reference		Reference
2–5	0.28 (0.26–0.30)	<0.001	0.22 (0.20–0.25)	<0.001	1.61 (1.52–1.72)	<0.001	1.79 (1.66–1.94)	<0.001
5+	0.44 (0.42–0.46)	<0.001	0.40 (0.38–0.42)	<0.001	0.99 (0.95–1.04)	0.654	0.97 (0.92–1.03)	0.357
AJCC stage		<0.001		<0.001
I	Reference		Reference		Reference		Reference
II	1.03 (0.97–1.10)	0.226	1.09 (1.01–1.17)	0.027	1.11 (0.96–1.28)	0.170	1.20 (1.01–1.42)\	0.035
III	2.82 (2.67–2.97)	<0.001	3.30 (3.09–3.52)	<0.001	1.58 (1.41–1.77)	<0.001	1.78 (1.56–2.03)	<0.001
IV	4.76 (4.51–5.03)	<0.001	5.80 (5.43–6.19)	<0.001	1.87 (1.61–2.18)	<0.001	2.23 (1.88–2.66)	<0.001
T stage		<0.001		<0.001
T1	Reference	<0.001	Reference		Reference		Reference
T2	1.06 (1.00–1.12)	0.039	1.11 (1.03–1.18)	0.003	1.12 (0.98–1.29)	0.094	1.13 (0.97–1.32)	0.125
T3	2.90 (2.77–3.05)	<0.001	3.30 (3.13–3.50)	<0.001	1.17 (1.06–1.30)	0.002	1.11 (0.99–1.25)	0.072
T4	3.41 (3.10–3.75)	<0.001	3.89 (3.49–4.34)	<0.001	1.35 (1.18–1.53)	<0.001	1.30 (1.13–1.50)	<0.001
N stage		<0.001		<0.001
N0	Reference		Reference		Reference		Reference
N1	2.95 (2.76–3.75)	<0.001	3.18 (2.95–3.42)	<0.001	1.07 (0.97–1.19)	0.184	1.04 (0.93–1.17)	0.506
M stage		<0.001		<0.001
M0	Reference		Reference		Reference		Reference
M1	3.81 (3.61–4.02)	<0.001	4.22 (3.97–4.49)	<0.001	1.54 (1.36–1.75)	<0.001	1.48 (1.28–1.70)	<0.001
Surgery		<0.001		<0.001
No/unknown	Reference		Reference		Reference		Reference
Performed	0.21 (0.20–0.23)	<0.001	0.18 (0.17–0.19)	<0.001	0.24 (0.22–0.25)	<0.001	0.21 (0.19–0.22)	<0.001
Radiation therapy		<0.001		<0.001
No/unknown	Reference		Reference		Reference		Reference
Performed	1.28 (1.20–1.36)	<0.001	1.36 (1.26–1.46)	<0.001	0.63 (0.59–0.67)	<0.001	0.62 (0.58–0.67)	<0.001
Chemotherapy		0.049		0.049
No/unknown	Reference		Reference		Reference		Reference
Performed	1.04 (1.00–1.09)	0.049	1.06 (1.01–1.12)	0.014	0.57 (0.54–0.59)	<0.001	0.55 (0.53–0.58)	<0.001

Note. HR, hazard ratio; CI, confidence interval.